6 results about "Cyclic lipopeptide" patented technology

The invention belongs to the technical field of biological extracts and cosmetics, and discloses a leukocyte extract composition as well as a preparation method and application thereof. The leukocyte extract composition comprises the following components in percentage by mass: 5-20% of a leukocyte extract; 3-10% of sodium surfactin; 10-20% of a humectant; and 50-82% of water. The preparation method of the leukocyte extract composition comprises the following preparation steps: adding the sodium surfactin into hot water at 50-80 DEG C for dissolving, then adding the humectant, homogenizing, stirring and uniformly mixing, cooling to room temperature, then adding the leukocyte extract, stirring and uniformly dissolving to obtain the leukocyte extract composition. According to the composition, a specific cyclic lipopeptide compound, namely, sodium surfactin, is adopted as a synergistic stable synergist of the leukocyte extract, so that the activity stability of the leukocyte extract can be remarkably improved, and better and more stable anti-aging, repairing and whitening effects can be achieved under the condition of smaller addition amount.

This invention discloses a cyclic lipopeptide delivery system, comprising a cyclic lipopeptide carrier and nucleic acid; the head of the cyclic lipopeptide carrier is composed of heptapeptides R1R2R2R3R4R2R2 linked together by amide bonds to form a ring, and the hydrophobic tail of the cyclic lipopeptide carrier is composed of a fatty acid with a carbon chain length of 6-44 forming an ester bond with the hydroxyl group on the head amino acid R3, with the following general structural formula: where R1 is a basic amino acid, including one of histidine (His), lysine (Lys), or arginine (Arg); R2 is a hydrophobic amino acid, including one of leucine (Leu), isoleucine (Ile), or valine (Val); R3 is a hydrophilic amino acid, including one of tyrosine (Tyr), serine (Ser), or threonine (Thr); R4 is one of glutamate (Glu) or glutamine (Gln); n is an integer from 5 to 43; the cyclic lipopeptide carrier encapsulates the nucleic acid drug to form cyclic lipopeptide-nucleic acid nanoparticles.

The application relates to a preparation method of natural cyclic lipopeptide nano-encapsulates with high oil content, and the steps are as follows: natural emulsifiers, glycerol, oil and water are weighed, the natural emulsifiers comprise sodium subtilipetrol and polyglycerol-10 oleate; the natural emulsifiers and the glycerol are mixed and heated and stirred, the oil is added after being dissolved, and a gel phase is obtained; water is added to the gel phase until the gel phase is completely dispersed, and natural cyclic lipopeptide nano-encapsulates are obtained. The compounding and synergistic effect of the sodium subtilipetrol and the polyglycerol-10 oleate is used in the application, compared with two single emulsifiers, the oil loading content is improved and the particle size is reduced. The natural nano-emulsion with high oil content prepared by the application has the advantages of low emulsifier dosage, simple process, small particle size (less than 600 nm), high oil content (more than 20%) of the prepared nano-emulsion, strong stability, high active substance loading content, good penetration effect and the like, is suitable for most liquid oils, and has high application value in the field of cosmetics.

This invention relates to the field of bactericide technology, specifically to a celandine bactericide and its preparation method. The bactericide is composed of the following parts by weight: antibacterial active ingredient: 0.1-0.5 parts; functional microbial agent: 2-20 parts; carrier: 70-90 parts; wherein the antibacterial active ingredient is composed of celandine and N-aryl-3,4-dihydroisoquinoline derivative in a mass ratio of 1:(0.2-5). This application introduces iodine and bromohalogen atoms at specific positions of N-aryl-3,4-dihydroisoquinoline, enabling it to produce a significant synergistic antibacterial effect with celandine. Beneficial bacteria such as Bacillus amyloliquefaciens and Pseudomonas fluorescens can resist the effects of sub-inhibitory drug concentrations by secreting cyclic lipopeptides and upregulating efflux pumps. The technology of encapsulating the antibacterial active ingredient into a sustained-release unit and combining it with a carrier that adsorbs live bacteria significantly improves the retention rate of live bacteria, achieving a long-term balance between stable drug release and beneficial bacterial activity.

The invention aims to provide a novel biological preservative based on barophila barophila and a preparation method of the novel biological preservative aiming at the problem that an active component extraction process is complex, the novel biological preservative comprises an active component A, an active component B and a microcapsule carrier, the active component A is a cyclic lipopeptide compound separated from barophila barophila sp.DP-2022-01 fermentation liquor, and the molecular formula of the active component A is C34H58N5O7; the active ingredient B is halogenated fatty acid which is separated from fermentation liquor of deep sea barophilic bacteria Shewanella sp.DP-2022-03, and the molecular formula of the halogenated fatty acid is C15H20C1O2; the microcapsule carrier is a gelatin-Arabic gum composite wall material in a mass ratio of 1: 1. The active component A (cyclic lipopeptide compound) inhibits gram-positive bacteria (such as listeria monocytogenes) by destroying the integrity of bacterial cell membranes, and the active component B (halogenated fatty acid) can interfere bacterial energy metabolism to inhibit gram-negative bacteria (such as escherichia coli); the combined use of the two can achieve the bacteriostasis rate of more than 95% on fungi such as staphylococcus aureus and candida albicans.

The present disclosure relates to a novel cyclic lipopeptide compound and a use thereof. More specifically, the present invention relates to a compound represented by chemical formula 1, an acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and to an antibacterial or biofilm formation inhibiting composition comprising the compound, the acceptable salt thereof, the stereoisomer thereof, the hydrate thereof, or the solvate thereof as an active ingredient.